Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010337 | 0.93 | EIF4A1 (0.34) | SIRT1TTRLMNA | |
| SCHEMBL1009527 | 0.91 | LMNA (0.35) | TTRCA12CA1CA7CA9 | |
| SCHEMBL23800865 | 0.90 | ODC1 (0.32) | LMNA | |
| SCHEMBL29565423 | 0.90 | ODC1 (0.32) | LMNA | |
| SCHEMBL1187759 | 0.88 | MAPT (0.33) | — | |
| SCHEMBL1009484 | 0.88 | HIF1A (0.38) | HTTLMNA | |
| SCHEMBL1010281 | 0.87 | RARA (0.38) | — | |
| SCHEMBL15318062 | 0.84 | ALK (0.36) | MRGPRX4LMNA | |
| SCHEMBL25844437 | 0.84 | CA12 (0.32) | CA12CA1CA7CA9CA13 | |
| SCHEMBL25605048 | 0.84 | CA12 (0.32) | SIRT1CA12CA1CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1872173-B9 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1872173-B1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090072206-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1872173-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1869140-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | Johnson and Johnson Vision Care, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110513-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006110221-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060226402-A1 | Ophthalmic devices comprising photochromic materials having extended PI-conjugated systems | KIM BEON-KYU | 2006-10-12 | — | — | US | disclosed |
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | INCENP, PCNA, INTS6 | SIRT1 2203/4885TTR 761/4885CA12 1603/4885 |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | INTS6, INCENP, PCNA | SIRT1 2551/4885TTR 936/4885CA12 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.